Insiders Load Up While Others Cash Out

Fresh filings this week reveal a sharp split in executive sentiment across US markets.

SMMT CEO Robert Duggan filed on June 12 that he bought $50M worth of Summit Therapeutics shares at $13.12 apiece. That's a striking vote of confidence in the biotech. President Maky Zanganeh also filed a $1.46M purchase days earlier. Two top executives buying at the same time is a rare signal worth watching.

NSP Chairman and CEO Paul Sarvadi disclosed a $7.9M purchase of Insperity stock on June 4, snapping up 233,000 shares at $34.05. Insperity has been under pressure. A CEO buying nearly $8M of his own stock sends a clear message.

FBIN saw activist investor Ed Garden pick up $13M in Fortune Brands Innovations shares. Garden joined the board via hedge fund Trian. The buy signals pressure for change.

On the sell side, AGX Chairman William Griffin filed a $32M sale of Argan shares on June 16. The stock trades near $643 — a record high. Marc Andreessen filed $26M in sales of IOT Samsara stock across two days. Lightspeed Venture Partners filed exits across NAVN Navan and NTSK Netskope totalling over $50M. Classic venture capital profit-taking after strong runs.

This is not financial advice.